Top Markets
Coin of the day
Novartis AG Novartis AG

Novartis AG

NOVN
주식 순위 #57
Novartis AG researches, develops, manufactures, distributes, markets, and sells... Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
주가
$149.90
마지막 동기화: 2026-09-18
시가총액
$284.92B
변동 (1일)
-0.66%
변동 (1년)
21.93%
국가
CH
거래 Novartis AG (NOVN)

카테고리

Novartis AG (NOVN)의 주식 분할 이력
Novartis AG 주식 (심볼: NOVN)은 총 2회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Oct 04, 2023에 발생했습니다.
May 07, 2001 이전에 매수한 NOVN 주식 1주는 현재 48주의 NOVN 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
2023-10-04 6:5 x1.2 x48
2001-05-07 40:1 x40 x40
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
4 x15
US
7 x432
US
0 -
US
2 x10000
CH
7 x226
US